The comparative in vitro activity and synergy of cefepime were evaluated with clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from cystic fibrosis patients. The activity of cefepime, both alone and in combination, was comparable to those of other antibiotics. The clinical efficacy of cefepime in cystic fibrosis patients merits investigation.
Cefepime is a new, broad-spectrum cephalosporin antibiotic with pronounced activity against many gram-negative pathogens (2, 6, 7) . It is more active than some of the currently marketed broad-spectrum cephalosporins against Pseudomonas aeruginosa and is stable against hydrolysis by common P-lactamases. Moreover , it has been found to be active against most gram-negative bacteria, including P. aeruginosa, that have developed resistance to other broadspectrum cephalosporins (3) . The objectives of the present study were to assess the comparative in vitro activity of cefepime against clinical isolates of P. aeruginosa and Pseudomonas cepacia obtained from cystic fibrosis patients and to determine the frequency of in vitro synergy in combinations of cefepime with other antipseudomonal agents against these same pseudomonal species.
Clinical isolates of P. aeruginosa (n = 100) and P. cepacia (n = 25) cultured from the sputa of cystic fibrosis patients and identified by standard microbiological methods were selected for the determination of the comparative activity of cefepime. Multiple isolates from the same patient were differentiated on the basis of colony morphology and antibiograms. (8) . The antibiotic concentrations inhibiting the growth of 50 and 90% of isolates (MIC50 and MIC90, respectively) and the percentage of isolates susceptible to each antibiotic were determined. In addition, the extent of activity of cefepime against isolates not susceptible to ceftazidime, tobramycin, and ciprofloxacin was assessed.
Isolates of P. aeruginosa (n = 100) and P. cepacia (n = 20) also derived from cystic fibrosis patient sputa and identified by standard methods were used to study synergy (most, but not all, were also used in the comparative activity component of this study). Two-drug combinations consisting of cefepime and ciprofloxacin, tobramycin, and aztreonam were evaluated. Synergy was determined by the standard checkerboard technique. MICs were determined by microbroth dilution testing as described above but with antibiotic concentrations ranging from 1,024 to 0.062 ,ug/ml. Ten microliters of a 1:100 dilution of bacterial broth was added to each microdilution well, which contained 100 ,ul of antibiotic solution, such that a final inoculum of 5 x 105 ,ug/ml was produced. Microtiter Rates of in vitro synergy are presented in Table 2 . While some synergy occurred with each combination, there were few cases in which an isolate was resistant to one or both antibiotics but in which the synergistic MICs of both agents were within the susceptibility ranges. No cases of antagonism were observed with any combination.
The newer beta-lactams, aztreonam and ceftazidime, have proven useful in cystic fibrosis patients infected with P. aeruginosa (1, 5, 9, 10) . Their efficacy in monodrug therapy has contributed to patient convenience and greater ease of home antibiotic therapy. On the basis of the results of this study, cefepime may also fit into this category. Its spectrum and degree of activity are very similar to those of ceftazi- Cefepime-aztreonam 44 (9) 25 (10) a Numbers in parentheses represent percentages of cases in which an isolate was resistant to one or both antibiotics but in which the synergistic MICs of both agents were within the susceptibility ranges.
dime. Fung-Tomc et al. reported a low rate of selection of resistant P. aeruginosa mutants by cefepime, lower than that by ceftazidime (4). In addition, cefepime resistance in ceftazidime-or cefotaxime-resistant P. aeruginosa mutants was rare. In contrast, we observed a low degree of activity of cefepime against ceftazidime-resistant isolates. The reasons for this discrepancy are unclear.
Taken as a whole, the results of this study and other studies support the further evaluation of cefepime for P. aeruginosa infections in cystic fibrosis patients. The efficacy and safety of cefepime, both alone and in combination with other antibiotics, for pulmonary exacerbations of cystic fibrosis associated with P. aeruginosa should be evaluated and compared with those of currently used antibiotic regimens.
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